It is expected to be able to show a difference in favor of the active treatment in the main variable, namely, reduction in triglycerides values at the end of the follow-up period (48 weeks) of at least 20% in magnitude, in the comparison of the means adjusted by a covariance analysis. According to the estimated standard deviation of 86 from our own data, consistent with literature data (AIDS 1999, 13:1424-1425), and the magnitude of the minimum effect pre-defined as relevant (20% reduction), it would be enough to some 29 evaluable patients per group. It is intended to recruit more patients as forecast of possible expected losses of about 10%, or in other words, 33 subjects per group.